Sector News

Pfizer, AZ, Moderna and more pledge not to rush COVID-19 vaccines

September 9, 2020
Life sciences

With President Donald Trump and others touting accelerated timelines for COVID vaccines—potentially ending in an emergency authorization before the U.S. election—public confidence in the process has taken a hit.

But nine biopharma CEOs are seeking to turn that sentiment around with a joint safety and efficacy pledge.
Tuesday, the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer and Sanofi vowed to not seek approvals or emergency use authorizations for their vaccine candidates without conclusive positive data.

The drugmakers will “only submit for approval or emergency use authorization after demonstrating safety and efficacy through a phase 3 clinical study that is designed and conducted to meet requirements of expert regulatory authorities such as FDA,” they said.

Pfizer CEO Albert Bourla last week said his company expects to know by late October whether its vaccine works. Aside from that drugmaker, Moderna and AstraZeneca are also in phase 3 testing in the U.S., but it’s unclear exactly when they could see early data.

Meanwhile, Trump and other officials in his administration have continued emphasizing that a vaccine is nearing.
On Friday, Trump said he spoke with Pfizer CEO Albert Bourla and that the company expects results “very, very shortly.” And in a Labor Day press briefing, Trump said a vaccine could be available by a “very special day,” appearing to reference the November 3 election.

The CDC is already working with states and localities to prepare for potential vaccine distribution as early as November 1. While the goal appears to center on the election, NIH director Francis Collins recently defended the effort, telling CNN the CDC is right to prepare for distribution in case any of the vaccines show early efficacy.

Even as the programs move ahead at record speeds, it’s “extremely unlikely, but not impossible” a vaccine will be ready in early November, Operation Warp Speed head and GlaxoSmithKline veteran Moncef Slaoui told NPR last week. He would resign if he felt inappropriate pressure to rush the process, he previously told Science.

By: Eric Sagonowsky

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend